# BMT CTN 1102

Source: https://onco.cc/trials/bmt-ctn-1102/  
OnCo record `bmt-ctn-1102` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BMT CTN 1102 settled whether older people with higher-risk myelodysplastic syndrome should be offered a stem-cell transplant: those who had a matched donor and went to transplant were far more likely to be alive three years later than those without a donor who had drug treatment instead, so transplant belongs in the plan for fit patients aged 50 to 75.

## Summary

BMT CTN 1102 was a multicentre biologic assignment trial of the Blood and Marrow Transplant Clinical Trials Network in 384 patients aged 50 to 75 with intermediate-2 or high-risk de novo myelodysplastic syndrome enrolled at 34 centres between 2014 and 2018. Patients were assigned to the donor arm (reduced-intensity allogeneic transplant) or the no-donor arm (hypomethylating therapy or best supportive care) according to whether a matched donor was found within 90 days of registration. The primary endpoint was overall survival at three years by intention to treat.

Adjusted three-year overall survival was 47.9 percent in the donor arm against 26.6 percent in the no-donor arm, an absolute difference of 21.3 percentage points, and leukaemia-free survival was 35.8 against 20.6 percent; the benefit held across every subgroup examined. The trial is the evidence that reduced-intensity transplant should be an integral part of management for fit older adults with higher-risk disease, which is how the corpus's myelodysplastic syndrome page cites it.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-22
- Also known as: BMTCTN1102; CTN 1102
- Tags: soc-trials
- Registry id: NCT02016781
- Phase: 2
- Setting: Intermediate-2 or high-risk de novo myelodysplastic syndrome in patients aged 50 to 75: assignment by donor availability within 90 days to reduced-intensity allogeneic transplant or to hypomethylating therapy or best supportive care, with three-year overall survival as the primary endpoint
- Sponsor: Medical College of Wisconsin
- Enrolled: 384
- Result: Three-year overall survival 47.9 percent with a donor and reduced-intensity transplant against 26.6 percent without a donor (p 0.0001); leukaemia-free survival 35.8 against 20.6 percent.
- Outcomes: Overall survival at 3 years (intention to treat, adjusted): Donor arm: reduced-intensity allogeneic transplant 47.9% vs No-donor arm: hypomethylating therapy or best supportive care 26.6%; Leukaemia-free survival at 3 years: Donor arm: reduced-intensity allogeneic transplant 35.8% vs No-donor arm: hypomethylating therapy or best supportive care 20.6%

## Sources

- ClinicalTrials.gov NCT02016781: https://clinicaltrials.gov/study/NCT02016781

## Connected records

- cancers: [Higher-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-higher-risk/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- technologies: [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/), [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/)
- institutions: [Medical College of Wisconsin Cancer Center](https://onco.cc/institutions/mcw-cancer-center/)
- key papers: [BMT CTN 1102: biologic assignment trial of reduced-intensity transplant by donor availability in patients aged 50 to 75 with advanced myelodysplastic syndrome](https://onco.cc/key-papers/paper-bmt-ctn-1102-transplant-older-mds-nakamura-jco-2021/)

---
JSON: https://onco.cc/api/v1/entities/bmt-ctn-1102.json